PHARNEXT news, videos and press releases - Page 3
For more news please use our advanced search feature.
PHARNEXT - More news...
PHARNEXT - More news...
- Pharnext Announces a €2.5m Loan Agreement with Néovacs
- Pharnext Appoints Antoine Gravelle as General Counsel
- Pharnext Appoints Antoine Gravelle as General Counsel
- Pharnext: Findings on Symptoms Burden of Charcot-Marie-Tooth Disease Type 1A From the ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the ICNMD 2022
- Pharnext: Findings on Symptoms Burden of Charcot-Marie-Tooth Disease Type 1A From the ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the ICNMD 2022
- Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors
- Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors
- Pharnext Announces Successful Debt Refinancing and New Loan Agreement
- Pharnext Announces Successful Debt Refinancing and New Loan Agreement
- Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase III Trial of PXT3003, the PREMIER Trial, for the Treatment of Charcot-Marie-Tooth Disease Type 1A
- Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase III Trial of PXT3003, the PREMIER Trial, for the Treatment of Charcot-Marie-Tooth Disease Type 1A
- New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time
- New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time
- Pharnext: The Latest Findings From CMT&Me, a ‘Real-World’ Digital Lifestyle Study on Charcot-Marie-Tooth Diseases (‘CMTs’), to be Presented at the 2022 Peripheral Nerve Society (‘PNS’) Annual Meeting
- Pharnext: The Latest Findings From CMT&Me, a ‘Real-World’ Digital Lifestyle Study on Charcot-Marie-Tooth Diseases (‘CMTs’), to be Presented at the 2022 Peripheral Nerve Society (‘PNS’) Annual Meeting
- Pharnext: Pharnext Reports Full Year 2021 Financial Results and Recent Business Updates
- Joshua Schafer Appointed as Interim Chairman of Pharnext Board of Directors
- Joshua Schafer Appointed as Interim Chairman of Pharnext Board of Directors
- Pharnext appoints Valérie Worrall as Chief Financial Officer
- Pharnext Appoints Valérie Worrall as Chief Financial Officer
- Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
- Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
- Pharnext and Global Tech Opportunities 13 Agree to Stop Convertible Bond Program from End of May 2022
- Pharnext and Global Tech Opportunities 13 Agree to Stop Convertible Bond Program from End of May 2022
- Pharnext appoints Dr. Burkhard Blank as new Chief Medical Officer and Head of Research & Development
- Pharnext Appoints Dr. Burkhard Blank as New Chief Medical Officer and Head of Research & Development
- Pharnext confirms details for 2021 Hybrid Research & Development Day
- Pharnext Confirms Details for 2021 Hybrid Research & Development Day
- Pharnext strengthens its management team with three key appointments to support ongoing development of PXT3003 toward approval and commercialization
- Pharnext Strengthens its Management Team with Three Key Appointments to Support Ongoing Development of PXT3003 Toward Approval and Commercialization
